Side effects do not warrant restrictions on use. Mefloquine for malaria prophylaxis;Profylactisch gebruik van mefloquine: Bijwerking geen reden tot verandering van indicatie

Pharmaceutisch Weekblad

Volumn 135, Issue 22, 2000, Pages 788-792

  Heeringa, M ^a   Van Grootheest, A C ^a  

^a NONE

Author keywords

Adverse effects; Malarials; Mefloquine; Primary prevention; Travel

Indexed keywords

MEFLOQUINE;

CARDIOTOXICITY; DEPRESSION; DRUG INDUCED DISEASE; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; MALARIA; MALARIA CONTROL; PLASMODIUM FALCIPARUM; PRIMARY PREVENTION; PSYCHOPATHY; REVIEW; SEIZURE; SKIN DEFECT;

EID: 0034595524     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Informatorium medicamentorum 2000. Den Haag: Koninklijke Maatschappij ter bevordering der Pharmacie, 2000:260-1.
2. Repertorium 98/99. Den Haag: Sdu, 1998.
3. Lobel HO, Kozarsky PE. Update on prevention of malaria for travelers. JAMA 1997;278:1767-71.
4. Croft A. Malaria prophylaxis. Toxicity of mefloquine is similar to that of other chemoprophylaxis. BMJ 1995;311:191-2.
5. Phillips MA, Kass RB. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996;3:40-5.
6. Hopperus Buma AP, Van Thiel PP, Lobel HO, et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996;173:1506-9.
7. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993;44:257-65.
8. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993;341:1299-303.
9. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993;45:430-75.
10. Van Puijenbroek EP, Meyboom RHB. Slaapstoornissen tijdens het gebruik van mefloquine. Pharm Weekbl 1995;130:477-9.
11. Van Riemsdijk MM, Van der Klauw MM, Van Heest JAC, et al. Neuro-psychiatric effects of antimalarials. Eur J Clin Pharmacol 1997;52:1-6.
12. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991;45:86-91.
13. Bem JL, Kerr L, Stürchler D Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992;95:167-79.
14. Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996;313:525-8.
15. Croft AMJ, World MJ. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet 1996;347:326.
16. Heeringa M, Kuster JAM, Meyboom RHB, et al. Convulsies tijdens profylactisch gebruik van mefloquine. Ned Tijdschr Geneeskd 1998;142:2477-80.
17. Review of central nervous system adverse events related to the antimalarial drug mefloquine (1985-1990) [WHO/MAL/91.1063]. Genève: World Health Organization, 1991.
18. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:963-72.
19. White AC Jr, Gard DA, Sessoms SL Cutaneous vasculitis associated with mefloquine. Ann Intern Med 1995;123:894
20. Van den Enden E, Van Gompel A, Colebunders R, et al. Mefloquine-induced Stevens-Johnson syndrome. Lancet 1991;337:683.
21. McBride SR, Lawrence CM, Pape SA, et al. Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. Lancet 1997;349:101.
22. Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996;42:415-21.
23. Richter J, Burbach G, Hellgren U, et al. Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Lancet 1997;349:101-2.
24. Jaspers CA, Hopperus Buma AP, Van Thiel PP, et al. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996;55:230-4.
25. Grieco A, Vecchio FM, Natale L, et al. Acute fatty liver after malaria prophylaxis with mefloquine. Lancet 1999;353:295-6.
26. Choo V. Uncertainty about mefloquine will take time to resolve. Lancet 1996;347:891.
27. Perry IC. Malaria prophylaxis. BMJ 1995;310:1673.
28. Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 1997;315:1412-6.
29. Croft AM, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 1997;91:199-203.
30. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993;341:848-51.
31. Van Grootheest AC, Van Puijenbroek EP, Heeringa M. Onrust ondermijnt objectieve beoordeling. Bijwerkingen van mefloquine. Pharm Weekbl 1999;134:114-6.